 Shares of InMed Pharmaceuticals Inc. INM, 52.16 rocketed 50.9 on very heavy volume in midday trading Wednesday, after the company said it was awarded a grant from the Natural Sciences and Engineering Research Council of Canada NSERC to support research and development of its cannabinoid drug candidates for the potential treatment of neurodegenerative diseases, such as Alzheimers, Parkinsons and Huntingtons. Trading volume spiked to 19.5 million shares, compared with the full-day average of about 148,200 shares. 